FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to novel compounds of formula I: where n has values 0 or 1, and Cy represents a heteroaryl group, selected from such groups as 2-furanyl, 3-furanyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl and 4-pyridinyl, where heteroaryl groups are optionally substituted by up to 3 substituents, different from hydrogen, independently selected from C1-6alkyl, C2-6alkenyl, C2-6alkinyl, C3-8cycloalkyl, substituted phenyl, furyl, halogen, -OR', -CF3, -CN, -NO2, -SO2R', -SO2NR'R″, -R'SO2R″, where R' and R″ are independently selected from hydrogen, C1-6alkyl, where the term "substituted", applicable with respect to substituted phenyl, relates to substitution with one or several halogens, and their pharmaceutically acceptable salts, as well as to pharmaceutical compositions based on the said compounds.
EFFECT: application of the said compounds for treatment and/or prevention of wide spectrum of CNS diseases and disorders.
13 cl, 2 dwg, 1 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
AMIDES OF DIAZABICYCLOALKANES, SELECTIVE WITH RESPECT TO ACETYLCHOLINE SUBTYPE OF NICOTINE RECEPTORS AND PHARMACEUTIC COMPOSITION AND METHODS OF TREATMENT WITH THEIR APPLICATION | 2007 |
|
RU2448969C2 |
RECEPTOR SUBTYPE-SELECTIVE AZABICYCLOALKANE DERIVATIVES | 2008 |
|
RU2417984C1 |
N,N'-SUBSTITUTED 3,7-DIAZABICYCLO[3.3.1]NONANES, PHARMACEUTICAL COMPOSITIONS BASED THEREON AND USE THEREOF | 2015 |
|
RU2613071C1 |
DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USING THEM | 2010 |
|
RU2549551C2 |
PHARMACEUTICAL COMPOUNDS | 2018 |
|
RU2767857C2 |
OXADIAZOLES AS MUSCARINIC RECEPTOR AGONISTS M AND/OR M | 2019 |
|
RU2817018C2 |
METHODS AND INTERMEDIATE COMPOUNDS | 2010 |
|
RU2531588C2 |
NON-COMPETITIVE NICOTINIC RECEPTOR ANTAGONISTS | 2011 |
|
RU2582339C2 |
METHODS AND INTERMEDIATE PRODUCTS | 2006 |
|
RU2446171C2 |
TREATMENT OF NEUROLOGICAL DISORDERS | 2017 |
|
RU2765868C2 |
Authors
Dates
2014-05-27—Published
2007-11-01—Filed